News

Abdera plans to ask regulators to greenlight a phase 1 trial with the DLL3-targeting therapy sometime in 2024. There are four additional targets that Abdera has declared but remain undisclosed.
Abdera launched in early 2021 backed by 8 million Canadian dollars in seed financing from adMare BioInnovations and AbCellera Biologics, a Vancouver-based antibody developer.
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a treatment aimed at neuroendocrine carcinoma. The biologic therapy is ...
Abdera’s lead program, ABD-147, is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225 Ac) to solid tumors expressing delta-like ligand 3 (DLL3 ...
SOUTH SAN FRANCISCO, Calif., April 23, 2025--Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and ...
Abdera’s R adio O ptimized V ector E nginee r ing (ROVEr™) platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel targets that ...
SOUTH SAN FRANCISCO, Calif., January 09, 2025--Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and ...
Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small ...
Abdera Therapeutics, a radiopharmaceutical start-up, has raised $142 million in series A and B financing. The series A round was led by Versant Ventures and Amplitude Ventures; ...
Abdera Therapeutics Inc. emerged from stealth mode with $142 million in equity funding and plans to develop a pipeline of radiopharmaceutical drugs that will employ engineered heavy-chain-only ...